← Leaderboards
Aaron Matthew Lebeau
University Of Wisconsin-Madison
$7,247,183
Attributed
$8,640,383
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,640,383 · 6
By mechanism
R01$7,026,039 · 5
T32$1,614,344 · 1
Top collaborators
- Daniel Schmidt4 shared
- Anjon Audhya3 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- John Bayouth$1,883,771
- Robert Jeraj$3,339,057
- Kevin Michael Johnson$4,917,690
- David J Beebe$20,083,426
- Christian Capitini$4,273,809
Others in their field
Other Emerging Leaders on “Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$169,304,044
- Yunda Huang · Fred Hutchinson Cancer Center$73,421,550
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Hanjoon Ryu$28,519,898
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
Research focus
AntibodiesDoseIn VivoMalignant Neoplasm Of ProstateXenograft ModelVariantGenerationsClinically RelevantCell LineBiodistributionEffective TherapyXenograft ProcedureLabelCombatInnovationTreatment EfficacyOverexpressionRadiolabeledTumorBiopsyLeadAndrogen ReceptorAndrogen Deprivation TherapyPhage Display
Grant awards (24)
Shark Radiotherapy for the Treatment of Triple-Negative Breast Cancer$630,171
R01 · FY2025 · CA · contact PI
Graduate Training in Molecular and Cellular Pharmacology$534,450
T32 · FY2025 · GM
Graduate Training in Molecular and Cellular Pharmacology$549,359
T32 · FY2024 · GM
Viral vector technology for cell type specific gene delivery$342,667
R01 · FY2024 · GM
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer$337,922
R01 · FY2024 · CA · contact PI
Graduate Training in Molecular and Cellular Pharmacology$530,535
T32 · FY2023 · GM
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer$348,592
R01 · FY2023 · CA · contact PI
Targeting CD133 for imaging and therapy in prostate cancer$348,592
R01 · FY2023 · CA · contact PI
Viral vector technology for cell type specific gene delivery$342,667
R01 · FY2023 · GM
Novel Radioimmunotherapy Strategies for Prostate Cancer$335,539
R01 · FY2023 · CA · contact PI
Viral vector technology for cell type specific gene delivery$144,056
R01 · FY2023 · GM
Targeting CD133 for imaging and therapy in prostate cancer$355,706
R01 · FY2022 · CA · contact PI
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer$348,592
R01 · FY2022 · CA · contact PI
Viral vector technology for cell type specific gene delivery$342,667
R01 · FY2022 · GM
Novel Radioimmunotherapy Strategies for Prostate Cancer$342,386
R01 · FY2022 · CA · contact PI
Targeting CD133 for imaging and therapy in prostate cancer$355,706
R01 · FY2021 · CA · contact PI
Novel Radioimmunotherapy Strategies for Prostate Cancer$342,386
R01 · FY2021 · CA · contact PI
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer$189,506
R01 · FY2021 · CA · contact PI
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer$164,411
R01 · FY2021 · CA · contact PI
Targeting CD133 for imaging and therapy in prostate cancer$351,057
R01 · FY2020 · CA · contact PI
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer$351,057
R01 · FY2020 · CA · contact PI
Novel Radioimmunotherapy Strategies for Prostate Cancer$350,651
R01 · FY2020 · CA · contact PI
Targeting CD133 for imaging and therapy in prostate cancer$351,057
R01 · FY2019 · CA · contact PI
Novel Radioimmunotherapy Strategies for Prostate Cancer$350,651
R01 · FY2019 · CA · contact PI